Juhani Saarinen

Company: Glykos Finland Oy

Job title: Chief Executive Officer

Seminars:

Novel MMAU Auristatin Glycoside ADC Against Melanoma – Stabilised Hydrophilic Linker-Payload Provides A Wide Therapeutic Window & Improved Potency 10:30 am

Review novel auristatin ADCs based on MMAU payload enable widening of therapeutic window compared to vedotin ADCs Discuss how high systemic and metabolic stability of cleavable glycopeptide linker improved both in vivo efficacy and tolerability Assess DAR4 and DAR8 MMAU ADCs against solid and heme malignanciesRead more

day: Conference Day Two